Skip to content

Study · Randomized controlled trial · n = 14 · 2012

3 results

Oxytocin increases amygdala reactivity to threatening scenes in females.

Lischke A, Gamer M, Berger C, Grossmann A, Hauenstein K, Heinrichs M, Herpertz SC, Domes G

Psychoneuroendocrinology23 Feb 2012Cited by 156 (Europe PMC)

PMID22365820 (opens in a new tab)DOI10.1016/j.psyneuen.2012.01.011 (opens in a new tab)PepBankPUB-22365820
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In 14 females, intranasal oxytocin increased amygdala reactivity to scenes depicting social threat compared with placebo.

    In plain wordsIn 14 women, oxytocin made the brain's amygdala respond more to threatening social scenes than placebo did.

    Peptide
    Oxytocin
    Outcome
    IncreaseAmygdala reactivity to social threat scenes
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Although OT had no effect on participants' gazing behavior, it increased amygdala reactivity to scenes depicting social and non-social threat.
    1 context sentence
    Summary · context
    To further explore whether OT generally enhances amygdala-dependent threat-processing in females, we used functional magnetic resonance imaging (fMRI) in a randomized within-subject crossover design to measure amygdala activity in response to threatening and non-threatening scenes in 14 females foll…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In 14 females, intranasal oxytocin increased amygdala reactivity to scenes depicting non-social threat compared with placebo.

    In plain wordsIn 14 women, oxytocin made the brain's amygdala respond more to threatening non-social scenes than placebo did.

    Peptide
    Oxytocin
    Outcome
    IncreaseAmygdala reactivity to non-social threat scenes
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Although OT had no effect on participants' gazing behavior, it increased amygdala reactivity to scenes depicting social and non-social threat.
    1 context sentence
    Summary · context
    To further explore whether OT generally enhances amygdala-dependent threat-processing in females, we used functional magnetic resonance imaging (fMRI) in a randomized within-subject crossover design to measure amygdala activity in response to threatening and non-threatening scenes in 14 females foll…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In 14 females, oxytocin had no effect on gazing behavior compared with placebo.

    In plain wordsIn 14 women, oxytocin did not change where the eyes looked, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeGazing behavior (eye movements)
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Although OT had no effect on participants' gazing behavior, it increased amygdala reactivity to scenes depicting social and non-social threat.
    1 context sentence
    Summary · context
    To further explore whether OT generally enhances amygdala-dependent threat-processing in females, we used functional magnetic resonance imaging (fMRI) in a randomized within-subject crossover design to measure amygdala activity in response to threatening and non-threatening scenes in 14 females foll…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT03081832

Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.

University Hospital, Toulousen = 34Jan 2017 to Dec 2018

Prader-Willi Syndrome

Trial pageClinicalTrials.govUpdated 30 Jan 2019
CompletedNot applicableNCT03114371

Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years

University Hospital, Toulousen = 4028 Nov 2016 to 11 Jan 2019

Prader-Willi Syndrome

Trial pageClinicalTrials.govUpdated 12 Nov 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.